Neurol. praxi. 2015;16(2):103-106

Clinically isolated syndrome and treatment with glatiramer acetate

MUDr. Radek Ampapa1, MUDr. Vladislav Cunder1, MUDr. Martin Svárovský2
1 Neurologické oddělení, Nemocnice Jihlava

This case report presents a patient with clinically isolated syndrome who has been treated with glatiramer acetate for nearly four years. The diagnosis was made based on the findings on magnetic resonance imaging and in the cerebrospinal fluid as well as according to a typical clinical course. The treatment was initiated after a short period of administration of interferon beta that had to be terminated due to the development of hepatopathy. The patient has had no further attacks while being treated with glatiramer acetate. Although the initial neurological signs were consistent with a severe relapse, there has been no progression of disability. Magnetic resonance imaging failed to show any new or enhancing demyelinating lesions. Despite expanding treatment options, glatiramer acetate remains an effective alternative in treating multiple sclerosis.

Keywords: clinically isolated syndrome, multiple sclerosis, glatiramer acetate

Published: May 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ampapa R, Cunder V, Svárovský M. Clinically isolated syndrome and treatment with glatiramer acetate. Neurol. praxi. 2015;16(2):103-106.
Download citation

References

  1. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo controlled trial. Lancet 2009; 374: 1503-1511. Go to original source... Go to PubMed...
  2. Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus H, Wolinsky J. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010; 16(3): 342-350. Go to original source... Go to PubMed...
  3. Havrdová E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology 2010; 74(Suppl 3): S3-7. Go to original source... Go to PubMed...
  4. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Copolymer 1 reduces relapse rate and improves disability in relapsing - remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo contolled trial. The copolymer 1 Multiple Sclerosis Group. Neurology 1995; 45(7): 1268-1276. Go to original source... Go to PubMed...
  5. Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M, Buccheister A, Hu J, Latif Z, Tselis A, Lisak R. Axonal metabolic recovery and potential neuroprotective affect of glatiramer acetate in relapsing-remitting multiple sclerosis. Multiple Sclerosis 2005; 11: 646-651. Go to original source... Go to PubMed...
  6. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013; 73(6): 705-713. Go to original source... Go to PubMed...
  7. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011; 69(2): 292-302. Go to original source... Go to PubMed...
  8. Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E, Weiss S, Shifroni G, Wolinsky JS, Filippi M. Long-term follow-up of patients treated with glatiramer acetate: A multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult Scler 2007; 13: 502-508. Go to original source... Go to PubMed...
  9. Schrempf W, Ziemssen T. Glatiramer acetate: Mechanism of action in multiple sclerosis. Autoimmun Rev 2007; 6: 469-475. Go to original source... Go to PubMed...
  10. Vaněčková M, Krásenský J, Horáková D, Mašek M, Burgetová A, Havrdová E, Seidl Z. Measurement of Corpus Callosum and Comparison of MRI Techniques for Monitoring of Multiple Sclerosis. Cesk Slov Neurol N 2012; 75/108(6): 742-747.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.